Ringer's Lactate (Lactated Ringer's / Hartmann's Solution)

Electrolyte Composition

Raw Chemical Content (per 100 mL)

Physical Properties

Comparison with Normal Saline and Plasma

Key Points

• Balanced crystalloid: RL is a "balanced" salt solution because its electrolyte profile closely mirrors extracellular fluid, unlike normal saline which has a supraphysiologic chloride load.
• Lactate metabolism: The 28 mEq/L of lactate is metabolized in the liver to bicarbonate, providing a mild buffering effect. It does NOT worsen lactic acidosis in shock states.
• No dextrose: Plain RL contains no glucose. RL + 5% dextrose is a separate formulation.
• SID (Strong Ion Difference): RL has an SID of ~28 mEq/L, which is lower than plasma (~40 mEq/L), making it slightly acidifying in large volumes compared to Plasma-Lyte.
• Calcium interaction: Contains calcium, so it should NOT be infused in the same line as blood products (Ca2+ can chelate citrate anticoagulant and cause clotting) or with medications that are incompatible with calcium (e.g., ceftriaxone in neonates).

Common Clinical Uses

• Fluid resuscitation in trauma, burns, and sepsis
• Perioperative fluid replacement (preferred over NS for most surgical cases)
• Replacement of GI losses (e.g., high ileostomy output)
• Parkland formula for burns: 4 mL/kg x %TBSA of RL in first 24 hours
• Preferred over normal saline in most situations to avoid hyperchloremic metabolic acidosis

Endpoints of Resuscitation

1. Traditional Clinical Endpoints

"ATLS guidelines define the correction of vital signs like blood pressure and heart rate as markers of adequate resuscitation. However, up to 82% of severely injured patients with normalized vital signs have ongoing occult ischemia..." - Mulholland & Greenfield's Surgery 7e

2. Global Perfusion Endpoints

A. Serum Lactate

• Target: <2 mmol/L, or clearance of ≥10% per 2 hours (lactate clearance)
• Elevated when ischemic tissue production exceeds hepatic/renal clearance
• Trend matters more than a single value - correction indicates adequate resuscitation
• Can be elevated by non-ischemic causes (accelerated glycolysis, liver failure, medications)

B. Base Deficit (BD)

• Target: >-6 mEq/L (less negative = better)
• Correlates with severity of shock and volume of blood transfused
• Classified: Mild (-3 to -5), Moderate (-6 to -9), Severe (>-10)
• Like lactate, a single value may represent past resolved deficit; the trend toward correction is the true endpoint
• Can be distorted by electrolyte abnormalities (hyperchloremia from NS, hypoalbuminemia)

C. Mixed/Central Venous Oxygen Saturation (SvO2 / ScvO2)

• SvO2 target: >65%; ScvO2 target: >70%
• Reflects the balance between oxygen delivery and consumption at the tissue level
• When DO2 falls, tissues extract more O2, reducing venous saturation
• In sepsis: SvO2 may be falsely elevated (>70%) due to mitochondrial dysfunction and arteriovenous shunting - a value <70% in sepsis signals both hypovolemic and septic shock
• Used in Early Goal-Directed Therapy (EGDT) protocols for sepsis

D. Central Venous Pressure (CVP)

• Target: 8-12 mmHg (8-12 in spontaneously breathing; higher in mechanically ventilated)
• A crude surrogate of preload/volume status
• Limited by mechanical ventilation, changes in ventricular compliance, and cardiac dysfunction
• No longer recommended in isolation as a resuscitation guide

E. Oxygen Delivery (DO2) and Consumption (VO2)

• Targeted via pulmonary artery catheter (PAC)
• "Supranormal" DO2 resuscitation (formerly advocated) has not consistently improved outcomes
• PAC use in critically ill trauma patients has not been shown to improve outcomes

3. Regional Perfusion Endpoints

"New methods for monitoring regional tissue perfusion and oxygenation are becoming available, the most promising of which are muscle tissue oxygen probes, near-infrared spectroscopy and sublingual capnometry." - Bailey & Love's Short Practice of Surgery 28e

4. Concept of Occult Hypoperfusion

• Patients with occult hypoperfusion >12 hours have 2-3x the mortality compared to those with a limited duration of shock
• Normalization of vital signs alone is an inadequate endpoint

5. Summary Table - Endpoint Classification

Practical Resuscitation Bundle (Sepsis - EGDT-derived)

• MAP >65 mmHg
• CVP 8-12 mmHg
• ScvO2 >70%
• Urine output >0.5 mL/kg/h
• Lactate normalization (<2 mmol/L) or clearance >10%

CHAPTER: MANAGEMENT OF BENIGN BREAST DISEASES

GENERAL PRINCIPLES OF MANAGEMENT

1. Clinical assessment - History and physical examination
2. Radiological assessment - Mammography (>35 years) and/or ultrasonography (<35 years)
3. Pathological assessment - Fine needle aspiration cytology (FNAC) or core needle biopsy (CNB)

ANDI CLASSIFICATION AND MANAGEMENT OVERVIEW

1. MASTALGIA (BREAST PAIN)

Classification

• Cyclical mastalgia - Pain linked to menstrual cycle; begins ~day 14, worsens until menstruation; bilateral; most common (65-70% of cases)
• Non-cyclical mastalgia - Not linked to cycle; may be localized ("trigger spot"); associated with duct ectasia, periductal mastitis, musculoskeletal causes (Tietze's syndrome)
• Extra-mammary pain - Musculoskeletal, costochondritis, angina, biliary colic (referred)

Management

• After negative triple assessment, reassurance alone resolves symptoms in up to 85% of women with mild-to-moderate cyclical mastalgia
• Record a breast pain chart for 1 month to document the pattern

• Well-fitting supportive brassiere (worn day and night)
• Evening primrose oil (gamma-linolenic acid) 3g/day - mild benefit, well tolerated
• Reduce caffeine intake; low-fat diet
• NSAIDs (topical diclofenac applied to the breast)

2. FIBROADENOMA

Management Principles

Conservative Management (Observation)

• Age <30 years with typical features on USS and FNAC/CNB
• Size <3-4 cm
• No rapid growth
• No atypia on biopsy
• Patient reassured and concordant
• Core biopsy-proven concordant fibroadenoma without atypia (ASBrS/SBI 2025 Guidelines)

Medical Management

• Tamoxifen / Ormeloxifene - Regression observed in some cases; used in young women wishing to avoid surgery
• Anti-oestrogenic treatment can lead to involution in up to 30% of small fibroadenomas

Indications for Surgical Excision

1. Age >30 years
2. Size >3-5 cm
3. Rapid growth (>20% increase in 6 months)
4. Atypia or suspicious features on core biopsy
5. Suspicious features on imaging (microlobulation, posterior shadowing)
6. Family history of breast cancer
7. Patient's preference / significant anxiety
8. Indeterminate "cellular fibroepithelial lesion" on core biopsy (cannot exclude phyllodes)
9. Fibroadenoma in elderly patients (include rim of normal tissue due to risk of occult malignancy)

Operative Note: Excision of Fibroadenoma

• Confirm diagnosis with triple assessment
• Mark the lump in the standing/sitting position pre-operatively
• Consent: scar, bleeding, infection, recurrence, sensory changes, need for re-excision

• Periareolar (Langer's lines) incision for central/periareolar lesions - best cosmesis
• Radial incision - acceptable for peripheral lesions in younger women
• Submammary incision - for giant fibroadenoma or lesions near inframammary fold

1. Skin incision along planned line, carried through dermis
2. Dissect skin flaps using cutting diathermy or scissors to reach the lump
3. The fibroadenoma is identified by its white, glistening capsule
4. Enucleation: Hold the mass with Allis forceps or finger dissection; blunt dissection along capsular plane separating it from surrounding breast parenchyma - the mass "shells out" cleanly
5. Complete excision without transection of the mass (ASBrS 2025 - transection increases recurrence risk and impairs histopathological assessment)
6. In patients >30 years or elderly: excise with a 2-3 mm rim of normal surrounding tissue
7. Achieve haemostasis with bipolar diathermy
8. Specimen sent for histopathology (mandatory)
9. Wound closure: Absorbable sutures to approximate breast parenchyma (2/0 Vicryl); subcutaneous 3/0 Vicryl; subcuticular 4/0 Monocryl or Prolene for skin

• Supportive brassiere worn for 2-3 weeks
• Wound review at 1-2 weeks
• Histopathology review at 2-3 weeks
• Return to age-appropriate breast screening

3. PHYLLODES TUMOUR

Classification (Histological)

Management

• All phyllodes tumours require surgical excision - cannot be observed
• Core biopsy reported as "cellular fibroepithelial lesion" should be excised (cannot distinguish from fibroadenoma histologically)

Operative Note: Wide Local Excision of Phyllodes Tumour

1. Mark 2 cm clearance around the tumour pre-operatively with a skin marker
2. Elliptical skin incision including overlying skin (if tumour is large or skin is thinned)
3. Dissection through breast parenchyma maintaining the 2 cm margin
4. Include underlying pectoralis fascia in the excision specimen
5. Reconstruct breast tissue with mobilization of adjacent parenchymal flaps (oncoplastic technique for large defects)
6. Closure as per fibroadenoma excision

4. BREAST CYSTS

Management

• Asymptomatic simple cysts: No intervention required (Choosing Wisely - ASBrS)
• Symptomatic or anxious patient: Ultrasound-guided or palpation-guided aspiration
• If cyst disappears completely on aspiration and fluid is non-bloody: Discard fluid (cytology not required)
• If bloody aspirate: Send for cytology; arrange USS to confirm complete resolution
• If cyst recurs after >2 aspirations: Consider excision

• Core needle biopsy with clip marking
• Indeterminate/suspicious component: Surgical excision

Operative Note: Breast Cyst Aspiration

1. Patient supine, ipsilateral arm raised
2. Confirm cyst on USS and plan approach
3. Skin prep, sterile field
4. Local anaesthesia (1% lidocaine) to skin and subcutaneous tissue
5. 21G needle attached to 10 mL syringe introduced under real-time USS guidance into the cyst
6. Aspirate until cyst collapses completely; confirm on USS
7. Note fluid character (straw-coloured, green, brown = benign; bloody = suspicious)
8. Apply pressure dressing; reassess on USS

5. PERIDUCTAL MASTITIS AND BREAST ABSCESS

Periductal Mastitis

Conservative Management

• Antibiotics: Co-amoxiclav (625 mg TID × 2-3 weeks) OR Flucloxacillin + Metronidazole (covers anaerobes) OR Ciprofloxacin + Metronidazole
• Duration: 2-3 weeks
• Needle aspiration of fluctuant abscess under USS guidance
• Smoking cessation (strong association with periductal mastitis)
• Rule out TB (GeneXpert MTB/RIF on pus)

Lactational Mastitis Management

1. Continue breastfeeding / regular emptying (prevents milk stasis)
2. Antibiotics: Flucloxacillin 500 mg QID or Co-amoxiclav × 10-14 days (covers S. aureus)
3. Analgesics, warm compresses
4. If abscess forms: USS-guided aspiration (first line); repeat if needed
5. Incision and drainage reserved for: failure of aspiration, multiloculated collections, deep-seated abscess, skin necrosis

Operative Note: Incision and Drainage of Breast Abscess

• Non-lactational/subareolar abscess: Circumareolar incision at the areolar margin
• Peripheral abscess: Radial incision at point of maximum fluctuation (avoids major ducts)
• Avoid a dependent incision in the inframammary fold (poor drainage)

1. Incision through skin over the abscess
2. Blunt dissection with artery forceps through cavity (break loculations)
3. Drain all pus; send pus for culture and sensitivity, AFB, GeneXpert
4. Thorough washout with warm saline (0.9%)
5. Do NOT primarily close - pack cavity loosely with ribbon gauze soaked in povidone-iodine or leave drain
6. Wound left open to drain and heal by secondary intention
7. Daily dressings; wound re-examined in 48 hours

• In fit patients: Hadfield's operation (total duct excision / Patey's major duct excision) after the acute episode settles
• Fistula excision: Probe the fistulous tract and excise the entire tract with the ductal cone

6. DUCT ECTASIA

Management

Operative Note: Hadfield's Major Duct Excision (Total Duct Excision)

1. Circumareolar incision (around lower half of areola)
2. Raise skin flap to expose the base of the nipple
3. Insert fine lacrimal probe into the discharging duct to guide excision
4. Transfix the ductal complex at the base of the nipple with a stay suture
5. Excise a 2-3 cm length of the entire ductal cone (all major ducts) flush with the undersurface of the nipple
6. Specimen sent for histopathology
7. Haemostasis; pack residual cavity or close with absorbable sutures
8. Skin closed with interrupted 4/0 Prolene

7. NIPPLE DISCHARGE (SURGICAL APPROACH)

Indications for Surgical Duct Excision

• Persistent unilateral spontaneous nipple discharge
• Bloody or blood-stained discharge
• Discharge from a single duct
• Failure to identify causative lesion on imaging
• Intraductal papilloma confirmed on ductography/MRI/USS

Operative Note: Single Duct Excision (Microdochectomy)

1. Express discharge at the start of operation to confirm the duct and mark with a suture
2. Insert lacrimal duct probe into the culprit duct
3. Circumareolar incision; raise subareolar flap
4. Excise the probed duct along with the surrounding cone of tissue (2-3 cm length)
5. Send specimen in toto for histopathology
6. Close as per major duct excision

8. GRANULOMATOUS MASTITIS

Management

• Obtain core needle biopsy to confirm diagnosis and exclude carcinoma
• Exclude TB (histology, AFB staining, GeneXpert, cultures)
• Idiopathic granulomatous mastitis (IGM):
  • Mild: Observation (spontaneous resolution in some cases)
  • Moderate-severe: Corticosteroids (prednisolone 0.5-1 mg/kg/day, taper over 6-8 weeks)
  • Abscess: Drain if fluctuant
  • Refractory: Methotrexate or surgical excision
• Recurrence rate is high (~25-50%) regardless of treatment modality

9. FAT NECROSIS

Management

• Reassure patient (often presents as hard, irregular mass mimicking carcinoma)
• Triple assessment mandatory to exclude malignancy
• No treatment required once benign nature confirmed
• Surgical excision if diagnostic uncertainty persists or for cosmesis

SUMMARY TABLE: MANAGEMENT OF BENIGN BREAST CONDITIONS

RECENT EVIDENCE (2025)

• Biopsy-proven concordant fibroadenoma without atypia does not require excision unless symptomatic, large, or rapidly growing
• Complete excision without transection is recommended when surgery is performed
• Re-excision of benign phyllodes with positive margin is not routinely required
• Patients can return to age-appropriate screening without additional follow-up imaging

• Dark blue - Lump
• Medium blue - Lump + Pain
• Light blue - Pain
• Pale blue - Discharge

RANSON'S CRITERIA FOR ACUTE PANCREATITIS

A. NON-GALLSTONE (Alcoholic) PANCREATITIS

At Admission (5 criteria)

At 48 Hours (6 criteria)

B. GALLSTONE PANCREATITIS (Modified Criteria)

At Admission

At 48 Hours

Key differences in gallstone pancreatitis: higher age/glucose/WBC/LDH thresholds, lower fluid cutoff (4L vs 6L), PaO2 not included.

SCORING AND INTERPRETATION

MNEMONIC - "GA LAW" (at Admission) + "CHOBF" (at 48 h)

• Glucose >200
• Age >55
• LDH >350
• AST >250
• WBC >16,000

• Calcium <8
• Haematocrit fall >10%
• Oxygen (PaO2) <60
• BUN rise >5
• Fluid >6 L + Base deficit >4

PATHOPHYSIOLOGICAL BASIS OF EACH CRITERION

LIMITATIONS OF RANSON'S CRITERIA

1. Cannot be completed until 48 hours - no early complete assessment
2. Insensitive on admission (only 5/11 criteria available)
3. A meta-analysis of 110 studies found Ranson score is a poor predictor of severity and performs no better than clinical judgement alone
4. Does not account for organ failure directly
5. Cannot be used serially to monitor progress

COMPARISON WITH OTHER SCORING SYSTEMS

RANSON'S CRITERIA - ACUTE PANCREATITIS

AT ADMISSION (5 criteria) - Mnemonic: "GLAW + Age"

AT 48 HOURS (6 criteria) - Mnemonic: "HOBFC + Base"

SCORE INTERPRETATION

Score ≥ 3 = Severe pancreatitis → ICU admission warranted

WHY EACH PARAMETER MATTERS

KEY LIMITATIONS

• Score incomplete until 48 hours - cannot fully assess at admission
• Meta-analysis of 110 studies: performs no better than clinical judgement
• Cannot be used serially to track progress
• Superseded in many centres by APACHE II (repeatable) and BISAP (simpler, 5 parameters, 24h)

Books containing the Ranson mortality interpretation:

Most complete source for the mortality table:

"Morbidity and mortality rates correlate with number of criteria present: 0 to 2 criteria = 1% mortality; 3 or 4 criteria = 15% mortality; 5 or 6 criteria = 40% mortality"

Summary: Clinical Diagnosis of Benign Breast Disease (n = 100)

Key Observations:

1. Fibroadenoma was the most common benign breast disease, accounting for nearly half (45%) of all cases. This is consistent with published literature, where fibroadenoma is the leading benign breast condition in women of reproductive age.
2. Inflammatory conditions (Breast Abscess + Mastitis) together accounted for 27% of cases (27/100), forming the second largest group.
3. Fibrocystic Disease was present in 13% of cases, representing involutional changes in the breast parenchyma.
4. Others (15%) likely includes conditions such as duct ectasia, galactocele, phyllodes tumour, fat necrosis, and nipple discharge - as seen in Table 5 of your thesis.
5. The distribution reflects a predominantly young female population given the high proportion of fibroadenoma, which peaks in the second and third decades of life.

This distribution is in agreement with the ANDI (Aberrations of Normal Development and Involution) classification, where fibroadenoma represents the most common aberration of the reproductive phase.

SUMMARY

Clinicopathological Study of Benign Breast Disease

STUDY OVERVIEW

TABLE 2: CLINICAL FEATURES (n = 100)

TABLE 3: CLINICAL DIAGNOSIS (n = 100)

TABLE 5: DISEASE vs. CLINICAL PRESENTATION

CONSOLIDATED THESIS SUMMARY

1. Clinical Presentation

2. Disease Distribution

3. Disease-Symptom Correlation

• Fibroadenoma characteristically presented as a painless lump (38/45 cases = 84%), consistent with its smooth, mobile, rubbery nature.
• Breast abscess most commonly presented with lump and pain (11/14 = 79%), reflecting the acute inflammatory process.
• Mastitis showed the most varied presentation across all four symptom categories, with a significant proportion presenting with pain (4 cases).
• Duct ectasia was uniquely characterised by nipple discharge (5/6 cases = 83%), distinguishing it from all other pathologies in this series.
• Benign phylloides tumour predominantly presented as a lump (5/8 = 63%), mirroring fibroadenoma clinically.

4. Clinical Significance

• A breast lump as an isolated symptom was most strongly associated with fibroadenoma and phylloides tumour - both solid benign masses.
• Lump + pain was most frequently seen in breast abscess and mastitis - reflecting the inflammatory aetiology.
• Nipple discharge alone is a red flag symptom warranting duct excision; in this study it was exclusively due to duct ectasia.
• The absence of discharge in fibroadenoma, phylloides, and abscess reinforces disease-specific symptom patterns.

5. Conclusion

Word count guidance: This summary is ~450 words and can serve directly as the Summary/Discussion chapter of your thesis, or be condensed to ~200 words for the abstract section.

Summary: Table 3 – Clinical Diagnosis

Clinicopathological Study of Benign Breast Disease (n = 100)

Distribution of Cases

Summary Paragraph (thesis-ready)

Key Points

• Benign solid tumours (fibroadenoma + phylloides) dominated the series
• Inflammatory conditions formed the second largest group
• Involutional changes (fibrocystic disease, duct ectasia) were less common
• The distribution aligns with the ANDI classification - reproductive phase aberrations (fibroadenoma) outnumber involutional phase disorders
• All cases required triple assessment (clinical + radiological + pathological) for definitive diagnosis

Summary: Table 4 – Investigations Done

Clinicopathological Study of Benign Breast Disease (n = 100)

Summary Paragraph (thesis-ready)

Key Points

• Ultrasound was universal (100%) - the single most important investigation in this series, applicable across all age groups and all diagnoses
• FNAC in 72% confirms adherence to the triple assessment protocol for the majority of cases
• Ultrasound + FNAC together constitute two of the three arms of triple assessment - clinical examination being the third
• The combination of USS and FNAC achieves a sensitivity of >90% for benign breast disease diagnosis
• FNAC is especially valuable for fibroadenoma (the largest group, 45 cases) where cytology shows characteristic bare bipolar nuclei and cohesive epithelial sheets
• In the remaining 28% without FNAC, management was likely guided by highly concordant clinical and USS findings, or by alternative pathological methods (core biopsy / intraoperative frozen section / excision biopsy)

Clinical Significance

This table underscores the central role of non-invasive and minimally invasive diagnostics in benign breast disease. The use of USS in all cases reflects best practice - it is the first-line imaging modality for women under 35 years and complements mammography in older patients. FNAC in 72% of cases demonstrates a rigorous diagnostic approach, minimising the risk of missing an occult malignancy within a presumed benign lesion.

Summary: Table 6 – Quadrant-wise Distribution of Breast Diseases

Clinicopathological Study of Benign Breast Disease (n = 100)

Summary Paragraph (thesis-ready)

Key Observations

Clinical Significance

Knowledge of quadrant-wise distribution is important for surgical planning - incision placement, oncoplastic reconstruction, and sentinel node biopsy access. The predominance of lesions in the upper quadrants reinforces the need for thorough clinical examination of this region. Central lesions (duct ectasia) require periareolar or circumareolar incisions and awareness of nipple-areolar complex involvement during surgery.

Summary: Management Strategy

Clinicopathological Study of Benign Breast Disease (n = 100)

Summary Paragraph (thesis-ready)

• Reassurance - for patients with benign lesions confirmed on triple assessment where no active intervention was required (e.g., small fibroadenomas in young women, simple cysts)
• Antibiotics - for inflammatory conditions including mastitis and early/uncomplicated breast abscess
• Specific pharmacological agents including Tamoxifen (anti-oestrogen for mastalgia and fibroadenoma regression), Evening Primrose Oil (gamma-linolenic acid for cyclical mastalgia), and Vitamin E (adjunct antioxidant therapy for mastalgia)

• Excision of fibroadenomas (the largest surgical group)
• Incision and drainage / excision of breast abscesses
• Wide local excision of phylloides tumours
• Major duct excision for duct ectasia
• Excision biopsy for indeterminate or complex lesions

Key Observations

Overall Observation (from thesis text)

"In our study population of 100 cases, females of different age groups were included and were diagnosed with various benign breast disorders namely Fibroadenoma, Fibroadenosis, Mastitis, Granulomatous Mastitis etc. Out of the study population of 100 cases, 60% cases were managed surgically with Excision being the mainstay and 40% cases were managed conservatively."

Clinical Significance

1. Fibroadenoma - the most common diagnosis (45%) - frequently required excision due to size, patient age, or anxiety
2. Breast abscess (14%) required surgical drainage in cases resistant to aspiration
3. Phylloides tumours (8%) mandatorily require wide local excision

Summary: Table 8 – Histopathological Report

Clinicopathological Study of Benign Breast Disease (n = 100)

Summary Paragraph (thesis-ready)

Key Observations

Clinical Significance

The 100% histopathological concordance between clinical diagnosis and histopathology report across all seven pathologies is a major finding of this study. It confirms that when triple assessment is rigorously applied - combining clinical examination, ultrasonography, and FNAC - the pre-operative diagnosis of benign breast disease is highly accurate. This reduces unnecessary excision of benign lesions while ensuring that all excised specimens are confirmed pathologically, maintaining oncological safety.

The selective use of histopathology - sent only where surgical excision was performed - reflects evidence-based, judicious surgical practice in the management of benign breast disease.

COMPLETE THESIS SUMMARY

Clinicopathological Study of Benign Breast Disease

(n = 100 Cases)

TABLE: TRIPLE ASSESSMENT & MANAGEMENT SUMMARY

INTEGRATED SUMMARY OF ALL FINDINGS

1. Study Population

2. Clinical Features (Table 2)

3. Clinical Diagnosis (Table 3)

4. Investigations (Table 4)

5. Disease vs. Clinical Presentation (Table 5)

6. Quadrant Distribution (Table 6)

7. Management Strategy (Management Table)

8. Histopathological Report (Table 8)

CONCLUSION

1. Fibroadenoma is the most common benign breast lesion (45%), consistent with its prevalence in women of reproductive age
2. Breast lump is the dominant presenting symptom (87% of cases - lump alone or with pain)
3. Ultrasonography (100%) and FNAC (72%) form the backbone of triple assessment, achieving 89% diagnostic concordance
4. Upper quadrants harbour the majority of benign lesions (44%) due to greater breast tissue volume
5. Surgery (excision) was required in 60% of cases, with conservative management adequate in 40%
6. 100% histopathological concordance validates the accuracy of triple assessment and confirms the benign nature of all excised specimens
7. The ANDI classification accurately frames all findings - reproductive phase aberrations (fibroadenoma) predominate, followed by inflammatory conditions, and involutional disorders

This study affirms that meticulous application of triple assessment combined with individualised management - conservative where safe, surgical when indicated - is the gold standard approach to benign breast disease.